Therapure Biopharma Inc. has filed a preliminary prospectus with securities regulatory authorities in each of the provinces and territories of Canada in connection with a proposed initial public offering of securities.
The preliminary prospectus contains important information relating to these securities but remains subject to completion or amendment. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. A copy of the preliminary prospectus is available on SEDAR (www.sedar.com).
To contact Therapure for available investor information, please email email@example.com or phone 289-327-2619.
The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States unless pursuant to an exemption therefrom. Information on this page is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Therapure Biopharma Inc. in any jurisdiction in which such offer, solicitation or sale would be unlawful.